LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Royalty Pharma PLC (Class A)

Suletud

SektorTervishoid

33.81 0.24

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

33.54

Max

33.96

Põhinäitajad

By Trading Economics

Sissetulek

99M

433M

Müük

-26M

568M

P/E

Sektori keskmine

13.576

51.198

Aktsiakasum

1.057

Dividenditootlus

2.65

Kasumimarginaal

76.275

EBITDA

172M

534M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+24.4% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

2.65%

2.40%

Järgmine tulemuste avaldamine

7. aug 2025

Järgmine dividendimakse kuupäev

10. juuni 2025

Järgmine aktsia dividendi kuupäev (ex-date)

15. aug 2025

Turustatistika

By TradingEconomics

Turukapital

-252M

19B

Eelmine avamishind

33.57

Eelmine sulgemishind

33.81

Uudiste sentiment

By Acuity

50%

50%

167 / 380 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bullish Evidence

Royalty Pharma PLC (Class A) Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

2. juuni 2025, 10:49 UTC

Suurimad hinnamuutused turgudel
Omandamised, ülevõtmised, äriostud

Theravance Shares Rise Premarket on Sale of Trelegy Royalties

Võrdlus sarnastega

Hinnamuutus

Royalty Pharma PLC (Class A) Prognoos

Hinnasiht

By TipRanks

24.4% tõus

12 kuu keskmine prognoos

Keskmine 41.6 USD  24.4%

Kõrge 51 USD

Madal 33 USD

Põhineb 5 Wall Streeti analüütiku instrumendi Royalty Pharma PLC (Class A) 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

5 ratings

4

Osta

1

Hoia

0

Müü

Tehniline skoor

By Trading Central

33 / N/AToetus ja vastupanu

Lühikene perspektiiv

Bullish Evidence

Keskpikk perspektiiv

Weak Bearish Evidence

Pikk perspektiiv

Bullish Evidence

Sentiment

By Acuity

167 / 380 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Keskmine

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Royalty Pharma PLC (Class A)

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.